Special Section on Laser Applications in Life Sciences

Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization

[+] Author Affiliations
Kathrin M. Scherer

Research Complex at Harwell, Central Laser Facility, Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0FA, United Kingdom

University of Salford, Biomedical Research Centre, Salford, Greater Manchester M5 4WT, United Kingdom

Roger H. Bisby

University of Salford, Biomedical Research Centre, Salford, Greater Manchester M5 4WT, United Kingdom

Stanley W. Botchway

Research Complex at Harwell, Central Laser Facility, Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0FA, United Kingdom

John A. Hadfield

University of Salford, Biomedical Research Centre, Salford, Greater Manchester M5 4WT, United Kingdom

Anthony W. Parker

Research Complex at Harwell, Central Laser Facility, Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0FA, United Kingdom

J. Biomed. Opt. 20(5), 051004 (Oct 27, 2014). doi:10.1117/1.JBO.20.5.051004
History: Received August 8, 2014; Revised September 10, 2014; Accepted September 12, 2014
Text Size: A A A

Abstract.  The photoisomerization of relatively nontoxic E-combretastatins to clinically active Z-isomers is shown to occur in solution through both one- and two-photon excitations at 340 and 625 nm, respectively. The photoisomerization is also demonstrated to induce mammalian cell death by a two-photon absorption process at 625 nm. Unlike conventional photodynamic therapy (PDT), the mechanism of photoisomerization is oxygen-independent and active in hypoxic environments such as in tumors. The use of red or near-infrared (NIR) light for two-photon excitation allows greater tissue penetration than conventional UV one-photon excitation. The results provide a baseline for the development of a novel phototherapy that overcomes nondiscriminative systemic toxicity of Z-combretastatins and the limitations of PDT drugs that require the presence of oxygen to promote their activity, with the added benefits of two-photon red or NIR excitation for deeper tissue penetration.

Figures in this Article
© 2015 Society of Photo-Optical Instrumentation Engineers

Citation

Kathrin M. Scherer ; Roger H. Bisby ; Stanley W. Botchway ; John A. Hadfield and Anthony W. Parker
"Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization", J. Biomed. Opt. 20(5), 051004 (Oct 27, 2014). ; http://dx.doi.org/10.1117/1.JBO.20.5.051004


Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement
  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.